Skip to main content
ACoP 2024 Main banner
Final Program


Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Molly Zhao, PhD

Director
Gilead Sciences, New Jersey, United States

Molly Zhao is the Director of Clinical Pharmacology at Gilead Sciences, where she leads a team responsible for providing clinical pharmacology expertise across various phases of immuno-oncology and pediatric oncology drug development. She earned her Ph.D. with Dr. Mager at the University at Buffalo in the Department of Pharmaceutical Sciences, and also holds an M.S. from China Pharmaceutical University. Dr. Zhao has been actively involved in the ACoP, previously chairing the abstract committee at ACoP12. In addition, she contributes to working stream within the IQ consortium, advancing industry collaboration and innovation in clinical pharmacology.

Disclosure(s): Gilead Sciences: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Keymed Biosciences: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Presentation(s):